Zhitong Finance App News, Huahai Pharmaceutical (600521.SH) announced that the company's holding subsidiary Shanghai Huaotai Biopharmaceutical Co., Ltd. (“Huaotai”) plans to increase capital and expand shares and introduce external investors such as Yangtze River Delta Venture Capital Guidance Fund partnerships (limited partnerships). Investors in this round plan to invest no more than 350 million yuan in cash in total. It is estimated that the total share ratio after obtaining Huaotai's capital increase will not exceed 5.9829%. After the capital increase is completed, the company holds no less than 81.8643% of Huaotai's shares, and Huaotai will continue to be included in the scope of the company's consolidated statements.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.